Clinical Features and Outcomes of Patients with Double-Hit/Triple-Hit Multiple Myeloma Detected at Relapse

Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L et al (2019) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. The Lancet 394:29–38. https://doi.org/10.1016/S0140-6736(19)31240-1

CAS  Article  Google Scholar 

Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C et al (2020) Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 21:1630–1642. https://doi.org/10.1016/S1470-2045(20)30525-8

CAS  Article  PubMed  Google Scholar 

Voorhees PM, Investigators for the GT, Kaufman JL, Laubach J, Investigators for the GT, et al (2020) ;136:936–45. https://doi.org/10.1182/BLOOD.2020005288

Shah V, Sherborne AL, Walker BA, Johnson DC, Boyle EM, Ellis S et al (2018) Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia 32:102–110. https://doi.org/10.1038/LEU.2017.179

CAS  Article  PubMed  Google Scholar 

Baysal M, Demirci U, Umit E, Kirkizlar HO, Atli EI, Gurkan H et al Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance. Scientific Reports 2020;10. https://doi.org/10.1038/S41598-020-62885-0

Jin F, Kumar S, Dai Y (2019) The adverse double-hit effect of combining cytogenetic abnormalities and ISS stage III on the outcome of patients with newly-diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk 19:e68. https://doi.org/10.1016/J.CLML.2019.09.107

Article  Google Scholar 

Singh C, Panakkal V, Sreedharanunni S, Jandial A, Jain A, Lad D et al Presentation and Impact of Double and Triple hit Cytogenetics in Patients With Multiple Myeloma in the Real World. Clin Lymphoma Myeloma Leuk 2022. https://doi.org/10.1016/J.CLML.2022.03.005

Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M et al (2020) Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 34:1875–1884. https://doi.org/10.1038/S41375-020-0711-6

CAS  Article  PubMed  PubMed Central  Google Scholar 

Richardson PG, Oriol A, Larocca A, Bladé J, Cavo M, Rodriguez-Otero P et al (2021) Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol 39:757–767. https://doi.org/10.1200/JCO.20.02259

CAS  Article  PubMed  Google Scholar 

Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398:314–324. https://doi.org/10.1016/S0140-6736(21)00933-8

CAS  Article  PubMed  Google Scholar 

Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T et al (2021) Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 397:2361–2371. https://doi.org/10.1016/S0140-6736(21)00592-4

CAS  Article  PubMed  Google Scholar 

Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D et al (2020) Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 396:186–197. https://doi.org/10.1016/S0140-6736(20)30734-0

CAS  Article  PubMed  Google Scholar 

Reece D, Song KW, Fu T, Roland B, Chang H, Horsman DE et al (2009) Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 114:522–525. https://doi.org/10.1182/BLOOD-2008-12-193458

CAS  Article  PubMed  Google Scholar 

Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C et al (2010) Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone. Leuk 2010 24:3. https://doi.org/10.1038/leu.2009.273

Article  Google Scholar 

Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S et al (2013) Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leuk 2013 27:12. https://doi.org/10.1038/leu.2013.152

CAS  Article  Google Scholar 

留言 (0)

沒有登入
gif